PETAH-TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, received approval from the Israeli Ministry of Health (MoH) to conduct phase II clinical trial with orally-administered CF101 in the treatment of Glaucoma. Leading Medical Centers in Israel will enroll 40 patients with Glaucoma for the first cohort and will be treated for 16 weeks with CF101 or placebo. The study will be expanded to 2 additional cohorts upon successful conclusion of an interim analysis of the first cohort. The study will investigate the safety and efficacy of CF101 manifested by a decrease in the intraocular pressure. The trial protocol and the results will also be reported to the US FDA.
